Buscar
Mostrando ítems 1-2 de 2
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
(Lippincott Williams & Wilkins, 2017)
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the ...
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
(Aran Ediciones S.A., 2018)
Background and aims: infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of biosimilar treatments such as CT-P13 will hopefully improve the availability of biological therapies. ...